Copenhagen, 21 August 2009 - NeuroSearch's (NEUR.CO) interim report for the
first half-year 2009 will be on the agenda of a Board meeting scheduled for 26
August 2009 and be released immediately hereafter.

On the same day, a teleconference will be held at 3 pm Copenhagen time (2 pm
London time, 9 am New York time) where Flemming Pedersen, CEO, Anita Milland,
Vice President & CFO and Hanne Leth Hillman, Vice President & Director of
Investor & Capital Market Relations, will present the 2009 half-year report and
answer questions. The teleconference will be conducted in English and the
telephone number is +44 (0) 20 7162 0077. The corresponding PowerPoint
presentation will be available at www.neurosearch.com.


Contact person:

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103


About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. NeuroSearch's
pipeline of drug candidates comprises seven clinical (Phase I-III) development
programmes: Pridopidine (ACR16) for Huntington's disease (Phase III),
tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in
partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease
(Phase Ib), ACR343 for schizophrenia (Phase II ready), ABT-560 for the
treatment of various CNS disorders (Phase I) in collaboration with Abbott, and
NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.

presse.08.09 - q2 release date - uk.pdf